Drug Search Results
More Filters [+]

Ponesimod

Alternative Names: ponesimod, act-128800, ponvory
Latest Update: 2024-09-28
Latest Update Note: Clinical Trial Update

Product Description

Ponesimod is an orally active, selective S1P1R modulator that causes dose-dependent sequestration of lymphocytes in lymphoid organs. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/26770667/)

Mechanisms of Action: S1P1 Modulator

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Australia | Austria | Belgium | Canada | Chile | Croatia | Czech | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | Ireland | Italy | Korea | Latvia | Lithuania | Luxembourg | Netherlands | Norway | Poland | Portugal | Romania | Saudi Arabia | Serbia | Slovakia | Slovenia | Spain | Sweden | Switzerland | Taiwan | United Arab Emirates | United Kingdom | United States

Approved Indications: Multiple Sclerosis | Multiple Sclerosis, Relapsing-Remitting

Known Adverse Events: Hypertension | Respiratory Tract Infections

Company: Johnson & Johnson
Company Location: NEW BRUNSWICK NJ 08933
Company CEO: Joaquin Duato
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Ponesimod

Countries in Clinic: Austria, Belarus, Belgium, Bosnia, Bulgaria, Canada, Croatia, Czech Republic, Finland, France, Georgia, Germany, Greece, Hungary, Israel, Italy, Latvia, Lithuania, Mexico, Netherlands, Poland, Portugal, Romania, Russia, Serbia, Spain, Sweden, Switzerland, Turkey, Ukraine, United Kingdom, United States

Active Clinical Trial Count: 6

Highest Development Phases

Phase 3: Multiple Sclerosis|Multiple Sclerosis, Relapsing-Remitting

Phase 1: Healthy Volunteers

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

PIONEER

P3

Active, not recruiting

Multiple Sclerosis, Relapsing-Remitting

2027-10-27

OPTIMUM-LT

P3

Completed

Multiple Sclerosis

2024-01-16

86%

OPTIMUM LT

P3

Active, not recruiting

Multiple Sclerosis

2024-01-04

2009-011470-15

P2

Completed

Multiple Sclerosis, Relapsing-Remitting

2023-12-29

Recent News Events